Showing results (51-60 of 96) with videos related to
Sort By:
Pageof 10
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.Investigational New Drugs|September 15, 2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim, Michelle R Mahoney, Daniel Szydlo, et al.Plos One|September 19, 2014
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersLaura W Goff, Nilay Thakkar, Liping Du, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan, Mark Rosenthal, Siobhan Ng, et al.European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignanciesKian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 23, 2026
Evaluating Interim Progression: First Posttherapy 177Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CTAshwin Singh Parihar, Farrokh Dehdashti, Niharika Pant, et al.Pageof 10